The application was launched on December 7, 2022 at the Nakuru Level 5 Hospital, during the opening of a new hemophilia treatment centre (HTC) in Nakuru County. The mobile app will contribute directly to one of the key PACT Program objectives of increasing the identification of people with bleeding disorders. Over eight hundred people are registered in Kenya with bleeding disorders. Through the app, the KHA seeks to increase this number to a total of at least one thousand. By using this new app, the KHA will be able to reach many more people than was previously possible—particularly in areas with high population densities. David Kones, the Deputy Governor of Nakuru County and the honourable Jacqualine Osoro, Country Executive Committee (CEC) member responsible for Health and Sanitation, were both present at the ceremony.
A pilot training was completed in the Tana River county, and consultations were held with the county government of Nairobi. The next step is to begin training users. As part of the outreach and diagnosis activities under the PACT Program, the KHA will offer training to the Community Health Volunteer (CHV) group’s core members on bleeding disorders essentials, and how to use the new mobile app to help identify new patients. CHV supervisors will in turn then train other members in their organization.
In addition to the support already provided for the development of the app, the PACT Program will help KHA carry out further training and outreach project activities across six Kenyan counties in 2023: Nairobi, Kisii, Muranga, Kakamega, Kilifi and Meru.
Everyone at the Kenya Haemophilia Association (KHA) is looking forward to using the app to identify new patients and bring care to thousands of people who currently might not even know they have a bleeding disorder.
To find out more about the WFH Path to Access to Care and Treatment (PACT) Program, please click here.
The PACT (Path to Access to Care and Treatment) Program is supported by funding from Roche, our visionary partner; CSL Behring, Pfizer and Sanofi Genzyme, our leadership partners; and Bayer, Biotest and Grifols, our collaborating partners.